文献速递支持与姑息治疗

体重指数与20种特定癌症:观察性研究剂量反应荟萃分析的再分析

Body mass index and 20 specific cancers: re-analyses of dose-response meta-analyses of observational studies.
PubMed 文献 · Ann Oncol · 2018-01-01

该伞状综述重新分析了BMI与20种癌症风险的剂量反应荟萃分析,按预设标准将证据分级。结果显示,白血病、多发性骨髓瘤、胰腺癌、子宫内膜癌、直肠癌和肾细胞癌与BMI增加有令人信服的关联;黑色素瘤、非霍奇金淋巴瘤和食管腺癌为提示性证据;脑中枢神经系统肿瘤、乳腺癌、结肠癌、胆囊癌、肺癌、肝癌、卵巢癌和甲状腺癌为弱证据;膀胱癌、胃癌和前列腺癌无证据。

要点

  • 白血病、多发性骨髓瘤、胰腺癌、子宫内膜癌、直肠癌和肾细胞癌与BMI增加有令人信服的关联。
  • 黑色素瘤、非霍奇金淋巴瘤和食管腺癌为提示性证据。
  • 膀胱癌、胃癌和前列腺癌未发现与BMI相关的证据。

核心结论

  • BMI增加与癌症的关联因癌症类型而异,白血病、多发性骨髓瘤、胰腺癌、子宫内膜癌、直肠癌和肾细胞癌有令人信服的关联。

研究设计与样本

  • 伞状综述,重新分析BMI与20种特定癌症风险关联的剂量反应荟萃分析数据,并补充大数据或遗漏的个体研究。

主要发现

  • 令人信服的证据见于白血病、多发性骨髓瘤、胰腺癌、子宫内膜癌、直肠癌和肾细胞癌。
  • 提示性证据见于恶性黑色素瘤、非霍奇金淋巴瘤和食管腺癌。
  • 弱证据见于脑和中枢神经系统肿瘤、乳腺癌、结肠癌、胆囊癌、肺癌、肝癌、卵巢癌和甲状腺癌。
  • 无证据见于膀胱癌、胃癌和前列腺癌。

关键数值与推荐

  • 令人信服的证据定义为固定效应和随机效应荟萃分析均P<0.001、95%预测区间排除无效值、无大研究间异质性且无小研究效应。
  • 提示性证据定义为随机汇总效应P<0.05但95%预测区间包含无效值。
  • 弱证据定义为随机汇总效应P<0.05但95%预测区间包含无效值且存在大研究间异质性或小研究效应。

临床怎么用

  • 临床可依据证据等级对高BMI患者进行相应癌症风险咨询和筛查,尤其针对有令人信服关联的癌症类型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Objectives were to provide an overview and understand the strength of evidence and extent of potential biases and validity of claimed associations between body mass index (BMI) and risk of developing cancer. METHODS: We carried out an umbrella review and comprehensively re-analyzed the data of dose-response meta-analyses on associations between BMI and risk of 20 specific cancers (bladder, brain, breast, colonic, rectal, endometrial, gallbladder, gastric, leukemia, liver, lung, melanoma, multiple myeloma, non-Hodgkins lymphoma, esophagus, ovarian, pancreatic, prostate, renal, thyroid) by adding big data or missed individual studies. Convincing evidence for an association was defined as a strong statistical significance in fixed-effects and random-effects meta-analyses at P < 0.001, 95% prediction interval (PI) excluded null, there was no large between-study heterogeneity and no small study effects. Suggestive evidence was defined as meeting the significance threshold for the random summary effects of P < 0.05, but 95% PI included the null. Weak evidence was defined as meeting the significance threshold for the random summary effects at a P < 0.05, but 95% PI included the null and there was large between-study heterogeneity or there were small study effects. RESULTS: Convincing evidence for an association with BMI was detectable for six cancers (leukemia, multiple myeloma, pancreatic, endometrial, rectal, and renal cell carcinoma). Suggestive evidence was detectable for malignant melanoma, non-Hodgkins lymphoma, and esophageal adenocarcinoma. Weak evidence was detectable for brain and central nervous system tumors, breast, colon, gall bladder, lung, liver, ovarian, and thyroid cancer. No evidence was detectable for bladder, gastric, and prostate cancer. CONCLUSIONS: The association of increased BMI and cancer is heterogeneous across cancer types. Leukemia, multiple myeloma, pancreatic, endometrial, rectal, and renal cell carcinoma are convincingly associated with an increased BMI by dose-response meta-analyses.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Choi EK, Park HB, Lee KH, et al. Body mass index and 20 specific cancers: re-analyses of dose-response meta-analyses of observational studies. Ann Oncol. 2018. PMID: 29300814. doi:10.1093/annonc/mdx819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。